CoChat

Cellular senescence mediates fibrotic pulmonary disease

Open access

The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.

Overview

CoChat Summary

## TL;DR

This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.

## Key findings

  • In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
  • In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
  • In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
  • Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
  • In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
  • The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.

## Methods

  • Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
  • The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
  • Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.

## Limitations

  • The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
  • The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
  • Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/ncomms14532

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Biomarkers of cellular senescence in human IPF. (a) Transcriptional changes corresponding to senescence effectors (black), SASP growth factors (dark grey) and SASP matrix remodelling (light grey) genes that were identified in independent RNAseq (control n=19, IPF n=20) and microarray human lung IPF versus control data sets are shown. IPF samples analysed by microarray were severity classified by FVC as low (≥80%; n=17), moderate (50–80%; n=60) or severe (<50%; n=16) and compared with control (n=64) (q<0.05 for both RNAseq and microarray). Human lung tissue sections were IHC stained for p16 in b control and (c,d) IPF lung samples with (c) fibroblastic foci and (d) honeycomb lung depicted. p16-positive fibroblasts (stars) and epithelial cells (arrows) are indicated ( × 200 images). (e) Control (left panel) and IPF (right panel) lung sections were analysed for frequencies of DNA damage foci (γH2A.X, green) and telomere immuno-fluorescence in situ hybridization (red) within alveolar compartments. Arrows indicate γH2A.X foci co-localizing with telomeres (TAF) (scale bar, 5 μm), shown at higher magnification on the right (images are from maximum intensity projection). (f) Mean number of γH2A.X foci (left) and percentage of cells containing at least one TAF (right) were determined through quantification of Z-stack images with at least 100 cells per sample ( × 100 images) (mean±s.e.m.; control n=10 (grey), IPF n=27 (red); t-test *P≤0.05).
Figure 1 Biomarkers of cellular senescence in human IPF. (a) Transcriptional changes corresponding to senescence effectors (black), SASP growth factors (dark grey) and SASP matrix remodelling (light grey) genes that were identified in independent RNAseq (control n=19, IPF n=20) and microarray human lung IPF versus control data sets are shown. IPF samples analysed by microarray were severity classified by FVC as low (≥80%; n=17), moderate (50–80%; n=60) or severe (<50%; n=16) and compared with control (n=64) (q<0.05 for both RNAseq and microarray). Human lung tissue sections were IHC stained for p16 in b control and (c,d) IPF lung samples with (c) fibroblastic foci and (d) honeycomb lung depicted. p16-positive fibroblasts (stars) and epithelial cells (arrows) are indicated ( × 200 images). (e) Control (left panel) and IPF (right panel) lung sections were analysed for frequencies of DNA damage foci (γH2A.X, green) and telomere immuno-fluorescence in situ hybridization (red) within alveolar compartments. Arrows indicate γH2A.X foci co-localizing with telomeres (TAF) (scale bar, 5 μm), shown at higher magnification on the right (images are from maximum intensity projection). (f) Mean number of γH2A.X foci (left) and percentage of cells containing at least one TAF (right) were determined through quantification of Z-stack images with at least 100 cells per sample ( × 100 images) (mean±s.e.m.; control n=10 (grey), IPF n=27 (red); t-test *P≤0.05).CC BY · PubMed Central
Figure 2 Bleomycin-induced senescence in murine lung cells. (a–d) Gating strategy for isolation of fibroblasts, epithelial and endothelial cells from the lungs of mice 14 days post-aerosolized instillation of bleomycin (Bleo) or PBS. (a) Total single-cell suspensions (P1) were gated to exclude doublets (P2) and CD45+ cells (P3). (b) Fibroblasts (PDGFRα+, EPCAM−, CD31− and CD45−), (c) epithelial cells (EPCAM+, PDGFRα−, CD31− and CD45−) and (d) endothelial cells (CD31+, PDGFRα−, EPCAM−, CD45−) were sorted from the P3 population. The expression of p16, SASP genes (Mcp1, Pai1, Tnfα, Mmp10, Mmp12) and fibrotic genes (Col1a1 and Tgfβ) were quantified by RT–PCR and are expressed relative to Hprt levels in sorted populations of (e) fibroblasts, (f) epithelial cells and (g) endothelial cells (mean±s.e.m.; PBS n=8 (grey), Bleo n=6 (red); t-test, ***P<0.0005, **P<0.005, *P<0.05, ¥P≤0.07 and #P≤0.1.).
Figure 2 Bleomycin-induced senescence in murine lung cells. (a–d) Gating strategy for isolation of fibroblasts, epithelial and endothelial cells from the lungs of mice 14 days post-aerosolized instillation of bleomycin (Bleo) or PBS. (a) Total single-cell suspensions (P1) were gated to exclude doublets (P2) and CD45+ cells (P3). (b) Fibroblasts (PDGFRα+, EPCAM−, CD31− and CD45−), (c) epithelial cells (EPCAM+, PDGFRα−, CD31− and CD45−) and (d) endothelial cells (CD31+, PDGFRα−, EPCAM−, CD45−) were sorted from the P3 population. The expression of p16, SASP genes (Mcp1, Pai1, Tnfα, Mmp10, Mmp12) and fibrotic genes (Col1a1 and Tgfβ) were quantified by RT–PCR and are expressed relative to Hprt levels in sorted populations of (e) fibroblasts, (f) epithelial cells and (g) endothelial cells (mean±s.e.m.; PBS n=8 (grey), Bleo n=6 (red); t-test, ***P<0.0005, **P<0.005, *P<0.05, ¥P≤0.07 and #P≤0.1.).CC BY · PubMed Central
Figure 3 The secretome of senescent fibroblasts is profibrotic. IMR90 lung fibroblasts were exposed to irradiation (10 Gy). Twenty-one days later, senescence was confirmed by (a) SA-β-gal staining (scale bar, 100 μm) and (b) RT–PCR assessment of p16, p21, MCP1 and IL6 expression relative to TBP levels in 10 Gy exposed (red) and sham-treated (grey) cells (mean±s.e.m.; n=3, *P≤0.05), as well as (c) immunoanalysis of secreted SASP components within 10 Gy-exposed CM (SASP-CM), relative to CCM (mean±s.e.m.; n=4, **P<0.01, *P≤0.05, ¥P=0.08 and #P≤0.1.) (d) IMR90 cells were treated with media collected 21 days post 10 Gy, -sham exposure or control as follows: NCM (black), NCM+2 ng ml−1 TGFβ (orange), CCM (grey) or SASP-CM (red). IMR90 cells were treated with the indicated media for 72 h then immunostained for αSMA (green) and DAPI (blue). Percentage αSMA-positive cells were determined blindly, using a visual threshold (mean±s.e.m.; n=2–4 independent experiments; **P<0.01 and *P≤0.05). (e) IMR90 cells were plated onto 6.4 kPA matrices for traction force microscopy in the presence of the indicated media for 72 h. Representative traction heat maps, root mean square (RMS) traction and peak traction are depicted (mean±s.e.m.; n=2–4 independent experiments with a minimum of 20 independent cells per condition; **P<0.01 and *P≤0.05 versus control CM). (f) IMR90 cells were treated with indicated media for 72 h before RNA isolation. RT–PCR expression of ACTA2, COL1A1, COL1A2 and FN1 were measured relative to GAPDH levels (mean±s.e.m.; n=2–4 independent experiments, *P≤0.05). (g) Human primary lung fibroblasts were exposed to irradiation (10 Gy). Twenty days post irradiation, cells were treated with the indicated concentrations of DQ (yellow) or navitoclax (green). Cell viability 3 days after drug treatment was measured by ATPLite assays and is indicated as a percentage of plating density at day 0 of treatment. (mean±s.e.m.; n=4, t-test, ***P<0.001, **P<0.01 and *P≤0.05).
Figure 3 The secretome of senescent fibroblasts is profibrotic. IMR90 lung fibroblasts were exposed to irradiation (10 Gy). Twenty-one days later, senescence was confirmed by (a) SA-β-gal staining (scale bar, 100 μm) and (b) RT–PCR assessment of p16, p21, MCP1 and IL6 expression relative to TBP levels in 10 Gy exposed (red) and sham-treated (grey) cells (mean±s.e.m.; n=3, *P≤0.05), as well as (c) immunoanalysis of secreted SASP components within 10 Gy-exposed CM (SASP-CM), relative to CCM (mean±s.e.m.; n=4, **P<0.01, *P≤0.05, ¥P=0.08 and #P≤0.1.) (d) IMR90 cells were treated with media collected 21 days post 10 Gy, -sham exposure or control as follows: NCM (black), NCM+2 ng ml−1 TGFβ (orange), CCM (grey) or SASP-CM (red). IMR90 cells were treated with the indicated media for 72 h then immunostained for αSMA (green) and DAPI (blue). Percentage αSMA-positive cells were determined blindly, using a visual threshold (mean±s.e.m.; n=2–4 independent experiments; **P<0.01 and *P≤0.05). (e) IMR90 cells were plated onto 6.4 kPA matrices for traction force microscopy in the presence of the indicated media for 72 h. Representative traction heat maps, root mean square (RMS) traction and peak traction are depicted (mean±s.e.m.; n=2–4 independent experiments with a minimum of 20 independent cells per condition; **P<0.01 and *P≤0.05 versus control CM). (f) IMR90 cells were treated with indicated media for 72 h before RNA isolation. RT–PCR expression of ACTA2, COL1A1, COL1A2 and FN1 were measured relative to GAPDH levels (mean±s.e.m.; n=2–4 independent experiments, *P≤0.05). (g) Human primary lung fibroblasts were exposed to irradiation (10 Gy). Twenty days post irradiation, cells were treated with the indicated concentrations of DQ (yellow) or navitoclax (green). Cell viability 3 days after drug treatment was measured by ATPLite assays and is indicated as a percentage of plating density at day 0 of treatment. (mean±s.e.m.; n=4, t-test, ***P<0.001, **P<0.01 and *P≤0.05).CC BY · PubMed Central
Figure 4 Senescent cell clearance improves pulmonary and physical health in bleomycin injury. (a) Ink-Attac transgenic mice receiving bleomycin (Bleo) through aerosolized intratracheal instillation were randomized to receive vehicle (Veh), AP or DQ and compared with PBS-exposed mice treated with Veh. Treatment timeline is indicated. Mice were killed 3 weeks post challenge, a time point at which lung fibrosis peaks15 (haematoxylin and eosin (H&E) panels top: PBS, bottom: Bleo). Lung expression of (b) p16, (c) SASP factors Mcp1, Il6, Tnfα, Mmp3, Mmp12 and profibrotic factors Col1a1 and Tgfβ were quantified by RT–PCR and are expressed relative to Hprt levels. (d) Whole-body plethysmography was used to assess enhanced pause (Penh), an indirect measure of airway resistance. (e) Lung compliance was ascertained by FlexiVent forced oscillation technique at endpoint. (f) Twenty-one-day body weight (BW) was compared with baseline body weight. (g) Exercise capacity was assessed through a treadmill test; distances ran to exhaustion are depicted (mean±s.e.m.; PBS+Veh n=13 (grey), Bleo+Veh n=8 (red), Bleo+AP n=12 (blue), Bleo+DQ n=13 (yellow); linear regression model; ***P<0.0005, **P<0.005, *P≤0.05, ¥P=0.08 and #P=0.1).
Figure 4 Senescent cell clearance improves pulmonary and physical health in bleomycin injury. (a) Ink-Attac transgenic mice receiving bleomycin (Bleo) through aerosolized intratracheal instillation were randomized to receive vehicle (Veh), AP or DQ and compared with PBS-exposed mice treated with Veh. Treatment timeline is indicated. Mice were killed 3 weeks post challenge, a time point at which lung fibrosis peaks15 (haematoxylin and eosin (H&E) panels top: PBS, bottom: Bleo). Lung expression of (b) p16, (c) SASP factors Mcp1, Il6, Tnfα, Mmp3, Mmp12 and profibrotic factors Col1a1 and Tgfβ were quantified by RT–PCR and are expressed relative to Hprt levels. (d) Whole-body plethysmography was used to assess enhanced pause (Penh), an indirect measure of airway resistance. (e) Lung compliance was ascertained by FlexiVent forced oscillation technique at endpoint. (f) Twenty-one-day body weight (BW) was compared with baseline body weight. (g) Exercise capacity was assessed through a treadmill test; distances ran to exhaustion are depicted (mean±s.e.m.; PBS+Veh n=13 (grey), Bleo+Veh n=8 (red), Bleo+AP n=12 (blue), Bleo+DQ n=13 (yellow); linear regression model; ***P<0.0005, **P<0.005, *P≤0.05, ¥P=0.08 and #P=0.1).CC BY · PubMed Central
Figure 5 Retention of p16-positive cells impedes resolution of bleomycin lung injury. (a) Ink-Attac transgenic mice receiving bleomycin (Bleo) through aerosolized intratracheal instillation were randomized to vehicle (Veh), AP or DQ and were compared with PBS-exposed, Veh-treated mice. Mice were treated as indicated from day 14–28 (grey shading). Body weight (BW) was monitored daily and is depicted as change in grams relative to baseline (*P<0.05). (b) Endpoint (4 weeks post exposure) Penh levels were compared to Penh levels measured at treatment randomization (2 weeks post exposure). Lung p16 expression levels measured by RT–PCR (normalized to Hprt) were compared with endpoint (c) Penh, (d) airway compliance, (e) Mcp1, (f) Pai1, (g) Mmp10 and (h) Col1a1 expression in bleomycin-injured mice (mean±s.e.m.; PBS+Veh n=6 (grey), Bleo+Veh n=13 (red), Bleo+AP n=15 (blue), Bleo+DQ n=14 (yellow). Pearson's correlation statistics are indicated).
Figure 5 Retention of p16-positive cells impedes resolution of bleomycin lung injury. (a) Ink-Attac transgenic mice receiving bleomycin (Bleo) through aerosolized intratracheal instillation were randomized to vehicle (Veh), AP or DQ and were compared with PBS-exposed, Veh-treated mice. Mice were treated as indicated from day 14–28 (grey shading). Body weight (BW) was monitored daily and is depicted as change in grams relative to baseline (*P<0.05). (b) Endpoint (4 weeks post exposure) Penh levels were compared to Penh levels measured at treatment randomization (2 weeks post exposure). Lung p16 expression levels measured by RT–PCR (normalized to Hprt) were compared with endpoint (c) Penh, (d) airway compliance, (e) Mcp1, (f) Pai1, (g) Mmp10 and (h) Col1a1 expression in bleomycin-injured mice (mean±s.e.m.; PBS+Veh n=6 (grey), Bleo+Veh n=13 (red), Bleo+AP n=15 (blue), Bleo+DQ n=14 (yellow). Pearson's correlation statistics are indicated).CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations

61 more claims

Create a free account to see all 115 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 26

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

35 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 50 references

Cited by

Items 1,201–1,300 of 1,619

Metadata

Authors
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
Affiliations
  • Mayo Clinic (US)
  • Newcastle University (GB)
  • Scripps Research Institute (US)
Corresponding author
LeBrasseur, Nathan K.
Venue
Nature Communications
Published
2017-02-23
Volume
8
Issue
1
Pages
14532-14532
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2591114726
Cited by
1,613
References
52
Citations by year
2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
FWCI
91.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Mayo Clinic (UL1-TR000135)
  • Glenn Foundation for Medical Research
  • Louisiana Transportation Research Center
  • Georgia Clinical and Translational Science Alliance (UL1 TR000135)
  • Noaber Foundation
  • Fondation pour la Recherche Médicale
  • National Institutes of Health (UL1TR000135, 2r01hl092961-13)
  • Directorate for Biological Sciences
  • Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
  • National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
  • National Heart, Lung, and Blood Institute (R01-HL-092961)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
MeSH terms
Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.